Sanger sequencing versus INNO-LiPA ® HBV PreCore assay for routine detection of precore and basal core promoter mutations in Hepatitis virus B chronically-infected patients

We compared the Sanger sequencing and the commercial INNO-LiPA ® HBV assay for the routine detection of Precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically-infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and BCP mutations respectively.

Source: Diagnostic Microbiology and Infectious Disease - December 17, 2017 Category: Microbiology Authors: EK Alidjinou, L Bocket, V Pigot, V Lambert, C Hallaert, V Canva, D Hober Tags: Note Source Type: research